A preparation comprising probiotic strains belonging to the genera Bacillus sp., Lactobacillus sp., optionally Pediococcus sp. as viable cells or cytoplasmic extract thereof, and proteases, wherein the strains can degrade peptide sequences of gliadins. The preparation can be used to produce gluten-free foods from gluten-containing cereals or to treat gluten-related disorders.

The present invention relates to the treatment of diseases induced by Enterobacteriae. The inventors evaluated, in a multicellular in vitro model associating cells representing human enterocytes (Caco-2 cells), goblet mucus secreting cells (HT29-MTX) and M cells, whether Bacteroides fragilis, a non-enterotoxigenic strain, could be useful to limit the severity of the Salmonella Heidelberg infection, with an hypermutator phenotype, by analyzing their impact on growth and mucosal translocation. Thus, the present invention relates to a Bacteroides fragilis strain for use in the treatment of diseases induced by Enterobacteriae in a subject in need thereof.

Disclosed are microbial biomarkers and methods for accurate non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) in subjects. The microbial biomarkers include Lactococcus lactis as well as its strains and subspecies. The microbial biomarkers include Dorea sp. 5-2. The methods include measuring abundance or copy number of the one or more microbial biomarkers in a sample from the subject. The sample may be bodily fluid, mucus, or stool. Also described are methods of treating a subject with NAFLD by administering to the subject a composition containing Lactococcus lactis and/or Dorea sp. 5-2.

A probiotic composition comprised of a probiotic, a prebiotic, a complex-starch reducing enzyme, an enzymatic co-factor, and a pH modifier. The probiotic composition facilitates the creation of a biofilm within the GI tract of poultry that outcompetes and excludes pathogens. The probiotic composition can be incorporated into an eggwash and sprayed onto an egg, the sprayed egg developing a stable probiotic population within the GI tract of the pre-hatched chick. The probiotic composition can also be incorporated into poultry feed by applying the probiotic composition as a mash prior to pelleting. The probiotic composition can also be applied post-pelleting as a wet or dry spray, directly onto the pellets. In some instances, the probiotic composition can be added a drinking water source used by poultry as a water additive. Poultry that consume feed or water that contain the probiotic composition develop a stable probiotic population within their GI tracts.

The present invention relates to novel subspecies of Bacillus. The novel subspecies can improve health and performance of production animals. In one embodiment the Bacillus subtilis subspecies has activity against Clostridium perfringens and/or E. coli. The invention further relates to compositions comprising one or more strains of the Bacillus subtilis subspecies and to use of the strain(s) of the Bacillus subtilis subspecies in an animal feed.

A composition and method for administering an active agent to a pet, such as a dog, a cat or a horse. The composition may comprise a yogurt-based chewable delivery matrix and a plurality of water-soluble film pieces dispersed throughout the chewable delivery matrix. The composition may also comprise a delivery matrix having at least 15% by weight of crude protein and a plurality of water-soluble film pieces dispersed throughout the delivery matrix. The plurality of water-soluble film pieces encompass an active agent therein, wherein the active agent is rapidly released from the composition upon contact with saliva from the pet. At least a portion of the released active agents may be oromucosally absorbed by the pet.

The present invention concerns a method to modulate the level of or to modify a target molecule in a subject or an environment, said method comprising: administering in said subject or providing to said environment an engineered bacterial strain comprising (i) a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, wherein the expression of said molecule of interest modulates directly or indirectly the level of or modify the target molecule in said subject or environment, and (ii) a heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate, wherein said heterologous gene or gene set comes from another species than the engineered bacterial strain; and further administering to said subject, or providing to said environment, said rare carbohydrate; whereby the level of the target molecule in said subject or environment is modulated or the target molecule is modified in said subject or environment.

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

The present invention relates to a composition in powder form comprising probiotic bacteria and at least one iron source selected from ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof. Ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof advantageously do not cause significant inhibition or reduction in the viability of the bacteria and thus these iron sources are advantageously used to fortify a composition in powder form comprising probiotic bacteria.

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.